EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study

Chaoshuai Fan, Jiabang Yang, Yanni Peng, Juan Hu, Mingyue Cao, Ruobing Li, Dongmei Jiang, Tao Wang, Wen Luo, Li Chen, Yanrong Luo, Guihua Lu

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06834-3 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Chaoshuai Fan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. Hauptthemen laut MEDLINE: Rituximab, Lymphoma, Large B-Cell, Diffuse, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, Research Fund for the Basic Medical Research for the youth of the Changhai Hospital, Special Program for Clinical Medicine Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Rituximab has significantly improved outcomes of DLBCL patients when incorporated into first-line or second-line chemotherapy. However, whether its addition to conditioning regimens further improves efficacy remains controversial. In this study, we explored the efficacy and safety of Rituximab with CEAC conditioning, a regimen previously reported by our center. We compared the CEAC regimen with or without Rituximab in 80 DLBCL patients with propensity score matching method at a ratio of 1:1 (40 CEAC, 40 R-CEAC). The objective response rate (ORR) was 95% in the CEAC cohort compared to 93% in the R-CEAC cohort (P = 0.615). The complete response (CR) rate was 70% versus 60%, respectively (P = 0.348). The 3-year progression-free survival (PFS) of the CEAC cohort and the R-CEAC cohort were 73% (95% CI 61%-89%) versus 61% (95% CI 47%-79%) (HR 1.706, 95%CI 0.774–3.763, P = 0.178). The 3-year overall survival (OS) of the CEAC cohort and the R-CEAC cohort were both 79% (95% CI 67%-93%) (HR 1.083, 95%CI 0.418–2.808, P = 0.869). And 3-year cumulative incidence of relapse (CIR) was 21% (95% CI 6.8%-33%) and 38% (95% CI 18%-50%) (HR 1.842, 95%CI 0.779–4.339, P = 0.162) in the CEAC cohort and the R-CEAC cohort. For the safety profile, no difference was observed in adverse events. In conclusion, the addition of rituximab to the CEAC conditioning regimen did not improve survival outcomes and is not recommended for DLBCL patients undergoing ASCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabLymphoma, Large B-Cell, DiffuseHematopoietic Stem Cell TransplantationTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMalePropensity ScoreMiddle AgedAdultTransplantation, AutologousAgedCohort StudiesCarmustineCyclophosphamideCytarabineVincristineSurvival RateDexamethasoneMelphalanRetrospective StudiesDoxorubicin

Stichwörter der Autor:innen

Autologous stem cell transplantationCEAC regimenConditioning therapyDiffuse large b-cell lymphomaRituximab

Substanzen

RituximabCarmustineCyclophosphamideCytarabineVincristineDexamethasoneMelphalanDoxorubicin

Autor:innen und Institutionen

  • Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
  • Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. 754492838@qq.com.
  • Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. yuhe0628@163.com.
  • Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. 122158553@qq.com.
  • Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. lovelugh@163.com.

Förderung

  • China Postdoctoral Science Foundation
  • Research Fund for the Basic Medical Research for the youth of the Changhai Hospital
  • Special Program for Clinical Medicine Research

Zitieren

APA

Fan, C., Yang, J., Peng, Y., Hu, J., Cao, M., Li, R., Jiang, D., Wang, T., Luo, W., Chen, L., Luo, Y., & Lu, G. (2026). Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study. Annals of Hematology. https://doi.org/10.1007/s00277-026-06834-3

Vancouver

Fan C, Yang J, Peng Y, Hu J, Cao M, Li R, et al. Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study. Annals of Hematology. 2026. doi:10.1007/s00277-026-06834-3

BibTeX
@article{Fan2026,
  author = {Fan, Chaoshuai and Yang, Jiabang and Peng, Yanni and Hu, Juan and Cao, Mingyue and Li, Ruobing and Jiang, Dongmei and Wang, Tao and Luo, Wen and Chen, Li and Luo, Yanrong and Lu, Guihua},
  title = {Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06834-3}
}
Kostenlos starten →